Rapport Therapeutics, Inc. Share Price & Technical Analysis
RAPP · $39.71 (+5.28%)
Healthcare / Biotechnology
$39.71
+5.28%
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing…
Price chart
Seasonality
May has 1 positive and 1 negative years (last 3 years shown)
13% return in May, -28% avg return in past 3 year May month.
26% return in 2026, 55% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -11% | 8% | 11% | 5% | 13% | – | – | – | – | – | – | – | 26% |
| 25 | -9% | -36% | 4% | 15% | -28% | 36% | 30% | 25% | 68% | 1% | 3% | 3% | 111% |
| 24 | – | – | – | – | – | 29% | -5% | -5% | -5% | 20% | -11% | -24% | 0% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Strong
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.79B
P/E ratio
—
52W high
$42.27
52W low
$7.73
Volume
4,34,884
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Rapport Therapeutics, Inc. share price today?
- Rapport Therapeutics, Inc. (RAPP) last traded around $39.71 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does RAPP have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for RAPP. Download the app for real-time alerts.
- How can I analyze Rapport Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.